Skip to main content

Real-World Data


Conference Coverage
Study results show that immunotherapy is the most common next line of therapy after discontinuation of an EGFR-TKI and platinum-based chemotherapy for metastatic NSCLC.
A recent real-world study compared HCRU and costs associated with first-line ibrutinib monotherapy vs bendamustine plus…
Conference Coverage
Treatment guided by biomarker testing is associated with improved survival outcomes in patients with advanced or…
Conference Coverage
Patients with NSCLC who receive pembrolizumab with chemotherapy are more likely to remain on therapy past 90 days than…
Sandeep Voleti, BS, discusses a study evaluating monetary trends in Medicare reimbursement for radical hysterectomy and…
Back to Top